{"id":14416,"date":"2012-01-01T01:30:00","date_gmt":"2012-01-01T00:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/2012-innovazione-e-strategie-per-biopharma\/"},"modified":"2012-01-01T01:30:00","modified_gmt":"2012-01-01T00:30:00","slug":"2012-innovazione-e-strategie-per-biopharma","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/2012-innovazione-e-strategie-per-biopharma\/","title":{"rendered":"2012: Innovation and strategies for BioPHARMA"},"content":{"rendered":"

For more than a decade, pharmaceutical industry analysts have argued that the traditional blockbuster model of drug discovery and development is unsustainable, despite many years of investment in new life science technologies. Explanations have included failed innovation capability and low productivity, a focus on incremental rather than radical innovation, excessive regulatory barriers, and a lack of venture capital investment.<\/p>\n

On March 20, 2012 on the occasion of <\/u><\/font> Biologic Manufacturing World Asia Convention <\/strong><\/u>the sustainability of current pharmaceutical innovation strategies will be considered in the context of the challenges and opportunities posed by the life sciences. We will discuss how the regulatory system plays a predominant role in determining innovation trajectories. The benefits of 'smart regulation' will also be considered to conclude with some observations on the future of the big pharmaceutical companies. The key question will be whether the pharmaceutical R&D model is sustainable and, if not, what alternatives are available. Furthermore, it will be possible to identify:<\/font><\/p>\n

<\/font><\/p>\n

    \n
  1. <\/font>      The best model of pharmaceutical innovation<\/strong><\/font><\/li>\n
  2.      The new business opportunities and the creation of the new commercial value of the product offer<\/font><\/strong><\/li>\n
  3.      Which of the current pharmaceutical innovation strategies are sustainable<\/font><\/strong><\/li>\n<\/ol>\n

     <\/p>\n

    http:\/\/www.terrapinn.com\/exhibition\/biopharma-asia\/speaker-chihiro-YOKOTA.stm<\/em><\/p>\n

    Translation Riccardo Bevilacqua<\/strong><\/p>\n

     <\/p>\n

    Per più di un decennio, gli analisti dell’industria farmaceutica hanno sostenuto che il modello tradizionale di blockbuster sulla scoperta e lo sviluppo di nuovi farmaci e di sviluppo è insostenibile, nonostante i molti anni di investimenti in nuove tecnologie delle scienze della vita. Le spiegazioni hanno incluso il fallimento della capacità di innovazione e la …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14416","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14416"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14416\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}